Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
ELI-005
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/05/2021
Bevacizumab
Potential treatment - clinical evidence Used to treat other disease Other treatment Feb/05/2021
Interferon gamma
Potential treatment - pre-clinical evidence Natural product Antiviral Feb/05/2021
Yindan Jiedu
Potential treatment - clinical evidence Natural product Antiviral Feb/05/2021
Asenapine
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Feb/05/2021
Clomiphene
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Feb/05/2021
Vortioxetine
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Feb/05/2021
Traditional Indian Ayurvedic treatment regime
Potential treatment - clinical evidence Natural product Antiviral Feb/04/2021
Narlaprevir
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Feb/04/2021
Hinokiflavone
Potential treatment - theoretical effect Natural product Antiviral Feb/04/2021
Robustaflavone
Potential treatment - theoretical effect Natural product Antiviral Feb/04/2021
DREP-S
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/04/2021
DREP-Secto
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/04/2021
Rac5c
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/04/2021
Curcumin
Potential treatment - theoretical effect Natural product Antiviral Feb/03/2021
Gingerol
Potential treatment - theoretical effect Natural product Antiviral Feb/03/2021
Thapsigargin
Potential treatment - pre-clinical evidence Natural product Other treatment Feb/03/2021
mRNA-RBD
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/03/2021
LbuCas13a N3.2
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/03/2021
MVA/S
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/03/2021